William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS)

William Blair reaffirmed their outperform rating on shares of Merus (NASDAQ:MRUS) in a report published on Monday, RTT News reports.

A number of other research firms have also recently weighed in on MRUS. HC Wainwright boosted their target price on shares of Merus from $48.00 to $65.00 and gave the company a buy rating in a research note on Thursday, February 29th. Truist Financial started coverage on shares of Merus in a research note on Thursday, March 28th. They issued a buy rating and a $69.00 target price on the stock. BMO Capital Markets boosted their target price on shares of Merus from $49.00 to $58.00 and gave the company an outperform rating in a research note on Thursday, February 29th. StockNews.com cut shares of Merus from a hold rating to a sell rating in a research note on Monday, March 4th. Finally, Needham & Company LLC reiterated a buy rating and issued a $66.00 target price on shares of Merus in a research note on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $56.33.

Merus Stock Performance

Merus stock opened at $44.93 on Monday. Merus has a fifty-two week low of $18.21 and a fifty-two week high of $52.03. The firm’s 50-day simple moving average is $45.03 and its 200 day simple moving average is $33.58.

Merus (NASDAQ:MRUS) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.38). Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. The firm had revenue of $8.94 million for the quarter, compared to analysts’ expectations of $10.43 million. As a group, equities analysts expect that Merus will post -3.29 earnings per share for the current fiscal year.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new stake in Merus during the 1st quarter worth approximately $72,000. Sierra Summit Advisors LLC bought a new stake in Merus during the 4th quarter worth approximately $221,000. Parkman Healthcare Partners LLC increased its holdings in Merus by 20.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 157,817 shares of the biotechnology company’s stock worth $4,340,000 after acquiring an additional 27,082 shares during the period. Great Point Partners LLC bought a new stake in Merus during the 4th quarter worth approximately $550,000. Finally, ADAR1 Capital Management LLC bought a new stake in Merus during the 4th quarter worth approximately $660,000. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.